168 related articles for article (PubMed ID: 38059408)
1. Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer.
Lin L; Li H; Wang X; Wang Z; Su G; Zhou J; Sun S; Ma X; Chen Y; You C; Gu Y
Cancer Med; 2023 Dec; 12(24):21639-21650. PubMed ID: 38059408
[TBL] [Abstract][Full Text] [Related]
2. Effector memory cytotoxic CD3
Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
[TBL] [Abstract][Full Text] [Related]
3. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
[TBL] [Abstract][Full Text] [Related]
4. Histological spatial analysis on the induction of PD-L1
Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
[TBL] [Abstract][Full Text] [Related]
5. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract][Full Text] [Related]
9. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
[TBL] [Abstract][Full Text] [Related]
10. Subclassifying triple-negative breast cancers and its potential clinical utility.
Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
[TBL] [Abstract][Full Text] [Related]
11. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
12. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.
Leeha M; Kanokwiroon K; Laohawiriyakamol S; Thongsuksai P
Pathol Oncol Res; 2023; 29():1611162. PubMed ID: 37274773
[No Abstract] [Full Text] [Related]
14. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
Tomioka N; Hatanaka KC; Okuyama D; Watanabe KI; Yamamoto M; Maeda H; Tachikawa H; Kuwahara S; Shimizu A; Suzuki H; Hatanaka Y; Takahashi M
Breast Cancer; 2023 May; 30(3):497-505. PubMed ID: 36892732
[TBL] [Abstract][Full Text] [Related]
15. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast Cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract][Full Text] [Related]
17. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
18. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
19. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
